Warren Kotler, diagnosed eight years ago with Stage 4 metastatic breast cancer, has outlived his prognosis through various treatments, maintaining a high quality of life while facing ongoing fear.
Despite his extended survival against cancer, Kotler is worried it will eventually outsmart his treatments. With new drugs emerging, he hopes to 'stick around long enough' to benefit.
Truqap, a new drug for advanced HR positive, HER2-negative breast cancer, was approved in Canada but costs about $10,000 for a 28-day supply, which is not covered by provincial programs.
AstraZeneca, the manufacturer of Truqap, stated it cannot cover the expensive medication under a patient support program requested by Kotler's medical team, complicating access for patients like him.
Collection
[
|
...
]